Last reviewed · How we verify

NCT05082636

The Role of Programmed Death Ligand -1 (Pdl-1) in Lung Cancer

Completed Last updated 25 October 2021
What this trial tests

trial testing Observational Study ( Tissue Biopsy ) in Lung Cancer in 90 participants. Completed in 25 March 2021.

Timeline
15 June 2018
Primary endpoint
20 June 2020
25 March 2021

Quick facts

Lead sponsorAssiut University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment90
Start date15 June 2018
Primary completion20 June 2020
Estimated completion25 March 2021
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Adults 40 to 70, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was designed to investigate the correlation of lung cancer tissue expression of both PDL-1-mRNA ,vitamin D receptor (VDR) and level of vit.D in sera of lung cancer patients.These three biochemical markers may interact and play a role in lung cancer progression.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05082636.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing